How to Help Your Patients Save Money on Linzess: A Provider's Guide to Savings Programs

Medication cost is one of the most common reasons patients abandon or don't fill prescriptions—and with Linzess (linaclotide) costing $680–$736 per month at retail with no generic available until at least 2029, affordability is a genuine barrier to adherence. This guide gives prescribers, nurses, and care coordinators a comprehensive toolkit for helping patients access Linzess at a cost they can sustain.

Understanding the Linzess Cost Landscape in 2026

Before recommending savings strategies, it helps to know the actual cost structure for Linzess:

• WAC (Wholesale Acquisition Cost): $282.48/month as of January 2026
• Retail cash price: $680–$736 per 30-day supply (30 capsules, 145 mcg)
• With commercial insurance (Tier 2–3): $30–$75 per month copay; prior authorization may be required
• Medicare Part D: Tier 3 placement; ~$180 per Medicare Part D claim on average; $2,100 out-of-pocket cap in 2026
• With GoodRx/SingleCare: ~$252 for 30, 145 mcg capsules at participating pharmacies

No generic is available until at least March 2029 (72 mcg; Teva license), with 145 mcg and 290 mcg generics expected by early 2030. Until then, your patients need to navigate brand-name pricing.

Option 1: Linzess Savings Program (Commercially Insured Patients)

The manufacturer copay card is the most impactful savings tool for commercially insured patients. Key details for your practice:

• Reduces out-of-pocket cost to $30 for a 30-, 60-, or 90-day supply
• Maximum annual benefit: $2,280 per calendar year
• Eligibility: commercial prescription insurance only; patients must be 6 years or older with a valid Linzess prescription
• NOT eligible: Medicare, Medicaid, TRICARE, or other federal/state programs
• Enrollment: Text LINZESS to 59257, call 1-855-859-5614, or register at linzess.com/savings

Practical tip: Consider having your office print or display the savings card URL. Patients can often enroll on their smartphone before leaving the office.

Option 2: AbbVie Patient Assistance Foundation (Uninsured or Underinsured)

For patients without insurance or whose insurance doesn't cover Linzess and who have income-based financial need:

• Provides up to 12 months of Linzess at no cost to qualifying patients
• Patients with insurance or Medicare Part D may still be eligible as exceptions in some cases—call to confirm
• Requires physician signature—your office staff can help initiate the application
• Contact: 1-800-222-6885 or visit abbviepaf.org

Practical tip: If you see a high volume of uninsured or low-income patients, consider having PAP application forms pre-filled with practice information to streamline the process.

Option 3: Medicare Patients—Extra Help and Part D Strategies

Medicare patients cannot use the manufacturer savings card, but have meaningful options:

• Extra Help (Low Income Subsidy): For qualifying patients with limited income and resources, Extra Help reduces the Part D Linzess copay to as little as $12.65/month (2026). Refer patients to ssa.gov or call 1-800-772-1213.
• Part D out-of-pocket cap: 2026 brings a $2,100 annual out-of-pocket cap for Medicare Part D. Once this threshold is reached, the plan covers 100% of covered drug costs for the remainder of the year.
• Mail-order pharmacy: Medicare Part D mail-order pharmacies often provide 90-day supplies at a reduced per-unit cost versus monthly retail fills.

Option 4: Discount Cards as a Bridge

For patients waiting for insurance approval (PA pending) or those who don't qualify for other programs, GoodRx and SingleCare provide meaningful savings:

• GoodRx and SingleCare can reduce Linzess price from $736 to approximately $252 at participating pharmacies
• No enrollment required—just print or show the coupon on a phone at the pharmacy counter
• Can be used whether or not the patient has insurance, though Medicare beneficiaries cannot combine these with Medicare Part D simultaneously

Option 5: Prior Authorization and Formulary Exception Support

When insurance places Linzess on a non-preferred tier or requires PA:

• Submit a PA with documented diagnosis (IBS-C K58.0, CIC K59.04, or FC K59.00), symptom severity, and prior treatment failures
• Submit a formulary exception request with a letter of medical necessity if the drug is not covered or on a non-preferred tier
• Use AbbVie's HCP portal (linzesshcp.com) for formulary status lookup and PA support resources

Option 6: Consider Therapeutic Alternatives When Cost Is a Barrier

When savings programs don't provide enough relief and the patient cannot afford Linzess, a therapeutic switch may be the most practical option. See our Linzess alternatives guide for details. Lower-cost alternatives:

• Generic lubiprostone (Amitiza): $50–$200/month; approved for CIC in adults and IBS-C in adult women
• Generic prucalopride (Motegrity): Lower cost; approved for CIC in adults

Help Patients Find a Pharmacy With Linzess in Stock

Cost isn't the only barrier—pharmacy stocking also affects adherence. Direct patients (or your care coordinator) to medfinder for providers to quickly identify which pharmacies near the patient have Linzess in stock and can fill the prescription. Results are texted to the patient, removing the burden from your staff.